The German government has reportedly been engaged in tightly confidential talks with the US Department of Health for several months regarding pharmaceutical pricing. According to the news portal Politico, citing three individuals familiar with the discussions, this high-level dialogue between the Health and Economic Ministries and the US administration stems from a demand made by President Donald Trump. Trump allegedly pushed for Germany and other European nations to pay higher prices for medicines.
Washington has criticized the current system, arguing that while US high prices fund the research and development of new medicines, Europe benefits as a “free-rider.” Consequently, the US is exerting pressure on Berlin because the prices for patented drugs in Germany are significantly lower than in the United States.
However, the German government has rejected a drastic, blanket increase in pharmaceutical costs, citing the massive budget deficit in the Statutory Health Insurance system (GKV). Instead, Berlin aims to work with the US to find solutions that could encourage greater investment in domestic research and development.
The European Union is also keenly interested in the progress of these negotiations. Health Commissioner Olivier Vaarhelyi is currently in Berlin, where he is scheduled to meet with Health Minister Nina Warken and the European advisor to the Chancellor, Michael Clauß.
As a point of comparison, the UK has already secured a pharmaceutical agreement with the US, which guarantees duty-free exports for British manufacturers entering the American market. In return, the National Health Service (NHS) is expected to dedicate higher expenditure to US-produced medicines.
Neither the German Health and Economic Ministry nor the US Department of Health offered comment on the matter when approached for a statement.
